Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Date Submitted: December 8, 2009

*(use as many sheets as necessary)*

Sheet 1 of 6

| *Complete if Known* | |
|---|---|
| **Application Number** | 10/566,358 |
| **Filing Date** | 04/13/2006 |
| **First Named Inventor** | Dominique BOUREL |
| **Art Unit** | 1644 |
| **Examiner Name** | Ilia I. Ouspenski |
| **Attorney Docket Number** | 065691-0433 |



## U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No.[1] | Document Number Number-Kind Code[2] (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---|---|---|---|---|---|
| | | | | | |
| | | | | | |

## UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

| Examiner Initials* | Cite No.[1] | U.S. Patent Application Document Serial Number-Kind Code[2] (if known) | Filing Date of Cited Document MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---|---|---|---|---|---|
| | | | | | |
| | | | | | |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No.[1] | Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Documents | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T[6] |
|---|---|---|---|---|---|---|
| | A1 | EP 1 270 595 B1 | 01/02/2003 | Kyowa Hakko Kogyo Co., Ltd. | | |
| | A2 | EP 1 443 961 B1 | 08/11/2004 | Genentech, Inc. | | |
| | | | | | | |

## NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[6] |
|---|---|---|---|
| | A3 | Advanced Catalogue Search, ATCC Number CRL-1662, Product Description, [online] [retrieved on Sept. 22, 2009]. Retrieved from the Internet: <URL: mhtml:file://W:\Intellectual Property\APPLICATIONS\OPPOSITIONS\LFB\atcc crl ...>. | |
| | A4 | Advanced Catalogue Search, ATCC Number CRL-1823, Product Description [online] [retrieved on 09/22/2009]. Retrieved from the Internet: <URL: http://www.lgcstandards-atcc.org/LGCAdvancedCatalogueSearch/ProductDescription...>. | |
| | A5 | ALBERTS, et al., "Molecular Biology of The Cell, 3rd Ed., p. 1206, Ch. 23: *The Immune System*, Garland Publishing. | |
| | A6 | ARMSTRONG-FISHER et al., "Evaluation of a panel of human monoclonal antibodies to D and Exploration of the synergistic effects of blending IgG1 and IgG3 antibodies on their in vitro biologic function," *Transfusion*, Aug. 1999, pp. 1005-1012, Vol. 39. | |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.





ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

| Substitute for form 1449/PTO | | | | *Complete if Known* | |
|---|---|---|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** | | | | **Application Number** | 10/566,358 |
| | | | | **Filing Date** | 04/13/2006 |
| Date Submitted: December 8, 2009 | | | | **First Named Inventor** | Dominique BOUREL |
| | | | | **Art Unit** | 1644 |
| *(use as many sheets as necessary)* | | | | Examiner Name | Ilia I. Ouspenski |
| Sheet | 2 | of | 6 | Attorney Docket Number | 065691-0433 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---|---|---|---|
| Examiner Initials* | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[6] |
| | A7 | Blood Plasma, Wikipedia, [online] [retrieved on 09/22/2009]. Retrieved from the Internet: <URL: http://en.wikipedia.org/wiki/Blood_plasma>, 3 pages. Revision history of Blood plasma, Wikipedia, [online] [retrieved 09/22/2009]. Retrieved from the Internet: <URL: http://en.wikipedia.org/w/index.php?title=Blood_plasma&limit=500&action=history>, 18 pages. | |
| | A8 | BOYD et al., "The Effect of the Removal of Sialic Acid, Galactose and Total Carbohydrate on the Functional Activity of Campath-1H," *Mole. Immunol.*, 1995, pp. 1311-1318, Vol. 32, Nos. 17/18. | |
| | A9 | BRAND, A., "Immunosuppression and Immunomodulation," *Immunological and Infectious Diseases of the Peripheral Nerves*, Latov et al., editors, Cambridge University Press, Chapter 24, pp. 366-368, 1998. | |
| | A10 | BREDIUS et al., "Role of neutrophile FcγRIIa (CD32) and FcγRIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes," *Immunology*, 1994, pp. 624-630, Vol. 83. | |
| | A11 | CANT et al., "Glycosylation and functional activity of anti-D secreted by two human lymphoblastoid cell lines," *Cytotechnology*, 1994, pp. 223-228, Vol. 15. | |
| | A12 | CARROLL et al., "Mouse X human heterohybridomas as fusion partners with human," *J. Immunol. Methods*, 1986, pp. 61-72, Vol. 89, Elsevier. | |
| | A13 | CD61, Wikipedia, [online] [retrieved on 09/22/2009]. Retrieved from the Internet: <URL: http://en.wikipedia.org/wiki/CD61, 5 pages. Revision history of CD61, [online] [retrieved on 09/22/2009]. Retrieved from the Internet: <URL: http://en.wikipedia.org/w/index.php?title=CD61&action=history, 1 page. | |
| | A14 | CHOWDHURY et al., "Tailor-made antibody therapeutics," *Methods*, 2005, pp. 11-24, Vol. 36, Elsevier. | |
| | A15 | DUCROT et al., "Use of the DAF Assay to Assess the Functional Properties of Polyclonal and Monoclonal Rh D Antibodies," *Vox Sang*, 1996, pp. 30-36, Vol. 71. | |
| | A16 | GALILI et al., "A Unique Natural Human IgG Antibody with Anti-α-Galactosyl Specificity," *J. Exp. Med.*, Nov. 1984, pp. 1519-1531, Vol. 160. | |
| | A17 | GOOSSENS, et al., "Human monoclonal antibodies against blood group antigens. Preparation of a series of stable EBV immortalized B clones producing high levels of antibody of different isotypes and specificities," *J. Immunol. Methods*, 1987, pp. 193-200, Vol. 101, Elsevier. | |
| | A18 | GREENMAN et al., "Comparative efficiencies of bispecific F(ab')$_2$ and chimeric mouse/human IgG antibodies in recruiting cellular effectors for cytotoxicity via Fcγ receptors," *Cancer Immunol. Immunother.*, 1992, pp. 361-369, Vol. 34. | |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.





ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Date Submitted: December 8, 2009

*(use as many sheets as necessary)*

Sheet 3 of 6

| *Complete if Known* | |
|---|---|
| **Application Number** | 10/566,358 |
| **Filing Date** | 04/13/2006 |
| **First Named Inventor** | Dominique BOUREL |
| **Art Unit** | 1644 |
| **Examiner Name** | Ilia I. Ouspenski |
| **Attorney Docket Number** | 065691-0433 |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[6] |
|---|---|---|---|
| | A19 | HADLEY et al., "The functional activity of FcγRII and FcγRIII on subsets of human lymphocytes," *Immunology*, 1992, pp. 446-451, Vol. 76. | |
| | A20 | HSU et al., "Differential *N*-Glycan Patterns of Secreted and Intracellular IgG Produced in *Trichoplusia ni* Cells," *J. Biol. Chem.*, Apr. 1997, pp. 9062-9070, Vol. 272, No.14. | |
| | A21 | HUGHES-JONES et al., "Nucleotide sequences and three-dimensional modeling of the $V_H$ and $V_L$ domains of two human monoclonal antibodies specific for the D antigen of the human Rh-blood-group system," *Biochem. J.*, 1990, pp. 135-140, Vol. 268. | |
| | A22 | IP et al., "Structural Characterization of the *N*-Glycans of a Humanized Anti-CD18 Murine Immunoglobulin G," *Archives of Biochemistry and Biophysics*, Feb. 1991, pp. 387-399, Vol. 208, No. 2. | |
| | A23 | JEFFERIS et al., "IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation," *Immunol. Reviews*, 1998, pp. 59-76, Vol. 163. | |
| | A24 | KELER et al., "Bispecific antibody-dependent Cellular Cytotoxicity of HER2/*neu*-overexpressing Tumor Cells by Fcγ Receptor Type I-expressing Effector Cells," *Cancer Research*, Sept. 1997, pp. 4008-4014, Vol. 57. | |
| | A25 | KILMARTIN et al., "Rat Monoclonal Antitubulin antibodies Derived by Using a New Nonsecreting Rat Cell Line," *J. Cell Biol.*, June 1982, pp. 576-582, Vol. 93. | |
| | A26 | KLEIN et al., "Human recombinant anti-Rh(D) monoclonal antibodies: Improvement of biological properties by *in vitro* class-switch," *Human Antibodies*, 1997, pp. 17-25, Vol. 8, No. 1. | |
| | A27 | KUMPEL et al., "Activity and Fcγ receptor utilization of IgG anti-D monoclonal antibodies in monocytes chemiluminescence assays and lymphocyte ADCC assays," 4[th] Workshop on Mabs against human red blood cells and related antigens, PARIS, 19-20 July 2002, page 1. | |
| | A28 | KUMPEL et al., "Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed By-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity," *Hum. Antibod. Hybridomas*, 1994, pp. 143-151, Vol. 5. Nos. 3 and 4. | |
| | A29 | KUMPEL et al., "Heterogeneity in the ability of IgG1 monoclonal anti-D to promote lymphocyte-mediated red cell lysis, *Eur. J. Immunol.*, 1989, pp. 2283-2288, Vol. 19. | |
| | A30 | KUMPEL et al., "Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunication in Rh D- volunteers," *Blood*, 1995, pp. 1701-1709, Vol. 86, American Society of Hematology. | |
| | A31 | KUMPEL, B.M., "Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers," *Vox Sang.*, 2007, pp. 99-111, Vol. 93. | |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.





ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Date Submitted: December 8, 2009

*(use as many sheets as necessary)*

Sheet 4 of 6

| *Complete if Known* | |
|---|---|
| **Application Number** | 10/566,358 |
| **Filing Date** | 04/13/2006 |
| **First Named Inventor** | Dominique BOUREL |
| **Art Unit** | 1644 |
| **Examiner Name** | Ilia I. Ouspenski |
| **Attorney Docket Number** | 065691-0433 |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[6] |
|---|---|---|---|
| | A32 | KUMPEL, B.M., "Monoclonal anti-D for prophylaxis of RhD haemolytic disease of the newborn," *Transfus. Clin. Biol.*, 1997, pp. 351-356, Vol. 4. | |
| | A33 | LIFELY et al., "Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions," *Glycobiology*, 1995, pp. 813-822, Vol. 5, No. 8. | |
| | A34 | LUND et al., "Control of IgG/Fc Glycosylation: A Comparison of Oligosaccharides from Chimeric Human/Mouse and Mouse Subclass Immunoglobulin Gs," *Mole. Immunol.*, 1993, pp. 741-748, Vol. 30, No. 8. | |
| | A35 | MELAMED et al., "Requirements for the establishment of heterohybridomas secreting monoclonal human antibody to rhesus (D) blood group antigen," *J. Immunol. Methods*, 1987, pp. 245-251, Vol. 104, Elsevier. | |
| | A36 | MERRIAM-WEBSTER, Webster's Third New International Dictionary of the English Language Unabridged, 1961, p. 1761. | |
| | A37 | MORI et al., "Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies," *Cytotechnology*, 2007, pp. 109-114, Vol. 55. | |
| | A38 | NAKAMURA et al., "Chimeric Anti-Ganglioside $G_{M2}$ Antibody with Antitumor Activity," *Cancer Research*, Mar. 1994, pp. 1511-1516, Vol. 54. | |
| | A39 | PAPAC et al., "A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis," 1998, pp. 463-472, Vol. 8, No. 5. | |
| | A40 | PATERSON et al., "Variation in IgG1 heavy chain allotype does not contribute to differences in biological activity of two human anti-Rhesus (D) monoclonal antibodies," *Immunotechnology*, 1998, pp. 37-47, Vol. 4, Elsevier. | |
| | A41 | PRESTA, Leonard G., "Engineering of therapeutic antibodies to minimize immunogenicity and optimize function," *Advanced Drug Delivery Reviews*, 2006, pp. 640-656, Vol. 58, Elsevier. | |
| | A42 | PUTHALAKATH et al., "Glycosylation Defect in Lec1 Chinese Hamster Ovary Mutant Is Due to a Point Mutation in *N*-Acetylglucosaminyltransferase I Gene," *J. Biol. Chem.*, Nov. 1996, pp. 27818-27822, Vol. 271, No. 44. | |
| | A43 | RAJU et al., "Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics," *Glycobiology*, 2000, pp. 477-486, Vol. 10, No. 5. | |
| | A44 | REVILLARD, Jean-Pierre, *Immunologie*, 2d Ed., 1995, various chapters, DeBoeck Université. | |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.





ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Substitute for form 1449/PTO | | | | *Complete if Known* | |
|---|---|---|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** | | | | **Application Number** | 10/566,358 |
| | | | | **Filing Date** | 04/13/2006 |
| Date Submitted: December 8, 2009 | | | | **First Named Inventor** | Dominique BOUREL |
| | | | | **Art Unit** | 1644 |
| *(use as many sheets as necessary)* | | | | Examiner Name | Ilia I. Ouspenski |
| Sheet | 5 | of | 6 | Attorney Docket Number | 065691-0433 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---|---|---|---|
| Examiner Initials* | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[6] |
| | A45 | ROTHMAN et al., "Antibody-dependent Cytotoxicity Mediated by Natural Killer Cells is Enhanced by Castanospermine-induced Alterations of IgG Glycosylation," *Mole. Immunol.*, 1989, pp. 1113-1123, Vol. 26, No. 12. | |
| | A46 | SEGAL et al., "The Role of Non-immune IgG in Controlling IgG-Mediated Effector Functions," *Mole. Immunol.*, 1983, pp. 1177-1189, Vol. 20, No. 11. | |
| | A47 | SHAW et al., "Human Lymphocyte, Monocyte, and Neutrophil Antibody-Dependent Cell-Mediated Cytotoxicity toward Human Erythrocytes," *Cell. Immunol.*, 1978, pp. 122-133, Vol. 41. | |
| | A48 | SHIELDS et al., "Lack of Fucose on Human IgG1 *N*-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity," *J. Bio. Chem.*, July 2002, pp. 26733-26740, Vol. 277, No. 30. | |
| | A49 | SHINKAWA et al., "The Absence of Fucose but Not the Presence of Galactose or Bisecting *N*-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," *J. Biol. Chem.*, Jan. 2003, pp. 3466-3473, Vol. 278, No. 5. | |
| | A50 | SHITARA et al., "A new vector for the high level expression of chimeric antibodies in myeloma cells," *J. Immunol. Methods*, 1994, pp. 271-278, Vol. 167, Elsevier Science B.V. | |
| | A51 | SIBÉRIL et al., "Selection of a human anti-RhD monoclonal antibody for therapeutic use: Impact of IgG glycosylation on activating and inhibitory FcγR functions," *Clinical Immunol.*, 2006, pp. 170-179, Vol. 118, Elsevier. | |
| | A52 | TAKAHASHI et al., "Comparative Structural Study of the N-Linked Oligosaccharides of Human IgG Normal and Pathological Immunoglobulin G," *Biochemistry*, 1987, pp. 1137-1144, Vol. 26. | |
| | A53 | TANDAI et al., "Structural Study of the Sugar Moieties of Monoclonal Antibodies Secreted by Human-Mouse Hybridoma," *Archives of Biochemistry and Biophysics*, Dec. 1991, pp. 339-348, Vol. 291, No. 2. | |
| | A54 | TEILLAUD, Jean-Luc, "Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges," *Expert Opin. Biol. Ther.*, 2005, pp. S15-S27, Vol. 5, Suppl. 1, Ashley Publications. | |
| | A55 | UMAÑA et al., "Engineered glycoforms of an antineuro-blastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity," *Nature Biotechnology*, Feb. 1999, pp. 176-180, Vol. 17. | |
| | A56 | URBANIAK et al., "Prediction of the Outcome of Rhesus Haemolytic Disease of the Newborn: Additional Information Using an ADCC Assay," *Vox Sang.*, 1984, pp. 323-329, Vol. 46. | |
| | A57 | URBANIAK, S.J., "ADCC (K-Cell) Lysis of Human Erythrocytes Sensitized with Rhesus Alloantibodies," *British J. Haematology*, 1979, pp. 303-314, Vol. 42. | |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.





ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Date Submitted: December 8, 2009

*(use as many sheets as necessary)*

Sheet 6 of 6

| *Complete if Known* | |
|---|---|
| **Application Number** | 10/566,358 |
| **Filing Date** | 04/13/2006 |
| **First Named Inventor** | Dominique BOUREL |
| **Art Unit** | 1644 |
| **Examiner Name** | Ilia I. Ouspenski |
| **Attorney Docket Number** | 065691-0433 |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[6] |
|---|---|---|---|
| | A58 | WRIGHT et al., "Effect of Altered $C_H2$-associated Carbohydrate Structure on the Functional Properties and In Vivo Fate of Chimeric Mouse-Human Immunoglobulin G1, J. Exp. Med., Sept. 1994, pp. 1087-1096, Vol. 180, The Rockefeller University Press. | |
| | A59 | WRIGHT et al., "Effect of C2-Associated Carbohydrate Structure on Ig Effector Function: Studies with Chimeric Mouse-Human IgG1 Antibodies in Glycosylation Mutants of Chinese Hamster Ovary Cells," *J. of Immunol.*, 1998, pp. 3393-3402. | |
| | A60 | WRIGHT et al., "Effect of glycosylation on antibody function: implications for genetic engineering," *TIBTECH*, Jan. 1997, pp. 26-32, Vol. 15. | |
| | A61 | WRIGHT et al., "*In vivo* Trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure," *Glycobiology*, 2000, pp. 1347-1355, Vol. 10, No. 12. | |
| | A62 | YANO et al., "Analysis of N-linked oligosaccharides in the Fc region of an antibody," Experiment Summary, 16 pages, 23 June to 28 July, 2009. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| Examiner Signature | /Ilia Ouspenski/ | Date Considered | 01/11/2010 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.





ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./